A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
22 Jul 2021
22 Jul 2021
Historique:
received:
11
02
2021
accepted:
07
05
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
24
7
2021
Statut:
epublish
Résumé
The development of effective countermeasures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the COVID-19 pandemic, is a priority. We designed and produced ConVac, a replication-competent vesicular stomatitis virus (VSV) vaccine vector that expresses the S1 subunit of SARS-CoV-2 spike protein. We used golden Syrian hamsters as animal models of severe COVID-19 to test the efficacy of the ConVac vaccine. A single vaccine dose elicited high levels of SARS-CoV-2 specific binding and neutralizing antibodies; following intranasal challenge with SARS-CoV-2, animals were protected from weight loss and viral replication in the lungs. No enhanced pathology was observed in vaccinated animals upon challenge, but some inflammation was still detected. The data indicate rapid control of SARS-CoV-2 replication by the S1-based VSV-vectored SARS-CoV-2 ConVac vaccine.
Identifiants
pubmed: 34294728
doi: 10.1038/s41541-021-00352-1
pii: 10.1038/s41541-021-00352-1
pmc: PMC8298481
doi:
Types de publication
Journal Article
Langues
eng
Pagination
91Informations de copyright
© 2021. The Author(s).
Références
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
J Virol. 2006 Nov;80(21):10293-306
pubmed: 17041210
N Engl J Med. 2021 Mar 8;384(15):1466-1468
pubmed: 33684280
Science. 2020 Nov 27;370(6520):1110-1115
pubmed: 33037066
Nature. 2020 Jul;583(7818):830-833
pubmed: 32380511
Virology. 2019 Jul;533:77-85
pubmed: 31128495
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
Hum Vaccin Immunother. 2019;15(10):2269-2285
pubmed: 31368826
Nature. 2020 Sep;585(7824):268-272
pubmed: 32396922
J Virol. 2015 Jan;89(1):144-54
pubmed: 25320306
PLoS One. 2019 Oct 7;14(10):e0223684
pubmed: 31589656
Nat Commun. 2021 May 19;12(1):2938
pubmed: 34011939
Science. 2020 Aug 21;369(6506):1010-1014
pubmed: 32540901
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11359-65
pubmed: 8876140
J Virol. 2017 Jan 3;91(2):
pubmed: 27807241
Am J Respir Cell Mol Biol. 2011 May;44(5):725-38
pubmed: 21531958
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Cell. 2020 Aug 6;182(3):744-753.e4
pubmed: 32553273
J Gen Virol. 2005 May;86(Pt 5):1435-1440
pubmed: 15831955
Nat Rev Immunol. 2021 Feb;21(2):73-82
pubmed: 33340022
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Science. 2020 Sep 25;369(6511):1603-1607
pubmed: 32732280
Science. 2020 Sep 25;369(6511):1586-1592
pubmed: 32694201
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
J Virol. 1997 Aug;71(8):5982-9
pubmed: 9223488
Cell Host Microbe. 2020 Sep 9;28(3):465-474.e4
pubmed: 32798445
Emerg Infect Dis. 2020 Jun;26(6):1266-1273
pubmed: 32160149
Virology. 2008 Jun 20;376(1):165-72
pubmed: 18396306
Nature. 2020 Oct;586(7830):560-566
pubmed: 32854108
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Antib Ther. 2020 Apr;3(2):109-114
pubmed: 32566896
Nat Commun. 2020 Dec 16;11(1):6402
pubmed: 33328475